ArticleLipids in health and disease2025
Changes in polyunsaturated fatty acids are linked to metabolic syndrome in children with steroid-sensitive nephrotic syndrome-a clinical observation.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Broad-Spectrum Health to Targeted Prevention: A Review of Functional Foods in Chronic Disease Management.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveAlterations in lipid metabolic pathways constitute a pivotal characteristic of Steroid-Sensitive Nephrotic Syndrome (SSNS). Despite the significance, there has been scant exploration into the influence of polyunsaturated fatty acids (PUFAs) on metabolic syndrome (MetS) in children with SSNS. This study endeavors to elucidate the association between PUFAs and MetS in this specific pediatric population.
methodsThis study enrolled a total of 185 children aged 0-7 years with SSNS between May 2023 and May 2024. Based on international guidelines for MetS, patients were classified into a MetS group (n = 73) and a non-MetS group (n = 112). A healthy control group (n = 82) was also established. Surveys, anthropometric measurements, and blood samples were used to assess lipid profiles, glucose, insulin, and Hemoglobin A1C (HbA1C). The concentrations of serum PUFAs were quantitatively analyzed utilizing gas chromatography-mass spectrometry (GC-MS) techniques.
resultsThe MetS group exhibited significantly elevated levels of fasting blood glucose, triglyceride (TG), low-density lipoprotein (LDL) cholesterol, HbA1C, insulin, the ratio of TG to high-density lipoprotein (HDL) cholesterol, and the ratio of total cholesterol to HDL cholesterol compared to the non-MetS group. Significant differences were observed among healthy controls, MetS group, and non-MetS group in terms of ω-3 alpha-linolenic acid (ALA), ω-3 docosahexaenoic acid (DHA), ω-6 arachidonic acid, and ω-6 to ω-3 ratio.
conclusionsHigh ω-6 arachidonic acid, ω-6/ω-3 ratio and low ω-3 ALA and ω-3 DHA were associated with elevated TG levels. An elevation in TG concentrations among pediatric patients with SSNS may have been implicated to MetS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.